HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.

International Summit on Hematology and Blood Disorders

April 27-29, 2023 | Orlando, USA

April 27 -29, 2023 | Orlando, Florida, USA

Welcome Message

Welcome Message

Hematology Conferences

International Summit on Hematology and Blood Disorders, April 27 - 29, 2023 | Orlando, USA

Dear Hematology Congress visitors, it is an honor and pleasure to invite you to this meeting which is focused on hematology. There has been remarkable progress in this area, which is both of fundamental and clinical importance, resulting from the application of modern molecular technologies as well as a holistic approach to disease causation and treatment. Several aspects of this progress will be covered at this meeting. These encompass, clonal tracking and gene therapy; role played by pharma industry and others in new drug discovery; myeloma and other hematologic malignancies; studies on model organisms; and transplantation biology. Collective presentation and discussion of these and other hematological topics by highly qualified researchers in one time and place is certain to point the way for future directions and progress in this field.

Yours Sincerely
A C Matin
Stanford Medical School
United States

Welcome Message

Blood Disorder Conference

International Summit on Hematology and Blood Disorders, April 27 - 29, 2023 | Hybrid Event

Dear congress visitors, it is an honor and pleasure to write a few welcome notes. Hematological blood disorders, such as leukemias, lymphomas and auto- and alloimmune cytopenias continue to create great challenges to the medical and scientific communities. However, with the advent of monoclonal immunotherapeutics such as daratubumab (anti-CD38), Hu5F9-G4 (anti-CD47), eculizumab (anti-complement (C5)) and other biotechnology breakthroughs, targeted immunotherapy is becoming the treatment of choice for many hematological disorders.  Use of intravenous immunoglobulin (IVIG) is effective in ameliorating or preventing immune thrombocytopenia (ITP) and hemolytic disease of the fetus and newborn.  Investigators are working on small molecule development to inhibit Fc receptor-mediated phagocytosis and thus, have a treatment for acute immune-mediated hemolytic anemias.  Indeed, the future looks encouraging for novel targeted therapeutics to address hematological blood disorders.  An exciting aspect is the potential clinical use of biotechnologies such as CRISPR/Cas9 “gene editing” that may provide a means to correct genetic disorders leading to blood problems such as factors VIII and IX deficiencies and “fixing” other, congenital blood disorders, such as G6PD deficiency and sickle cell anemia.  I look forward to a very productive and informative Summit.

Yours Sincerely
Prof. Donald R. Branch, University of Toronto, Toronto, Canada

Watsapp